6.58
+0.39(+6.30%)
Currency In USD
| Previous Close | 6.19 |
| Open | 6.13 |
| Day High | 6.89 |
| Day Low | 6.03 |
| 52-Week High | 11 |
| 52-Week Low | 3.71 |
| Volume | 778,003 |
| Average Volume | 452,640 |
| Market Cap | 141.41M |
| PE | -1.91 |
| EPS | -3.44 |
| Moving Average 50 Days | 5.79 |
| Moving Average 200 Days | 5.32 |
| Change | 0.39 |
If you invested $1000 in Unicycive Therapeutics, Inc. (UNCY) since IPO date, it would be worth $131.6 as of January 21, 2026 at a share price of $6.58. Whereas If you bought $1000 worth of Unicycive Therapeutics, Inc. (UNCY) shares 3 years ago, it would be worth $1,080.46 as of January 21, 2026 at a share price of $6.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
GlobeNewswire Inc.
Dec 29, 2025 12:05 PM GMT
New PDUFA date expected in 1H 2026 within 30 days of NDA resubmissionLOS ALTOS, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
GlobeNewswire Inc.
Nov 25, 2025 12:05 PM GMT
LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shal
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
GlobeNewswire Inc.
Nov 03, 2025 12:05 PM GMT
LOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shal